COMP <GO>
EHC vs ABBV // FORWARD P/E MULTIPLE
Encompass Health Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: EHC 6
— ABBV 9
▲ FORWARD P/E MULTIPLE LEADER: EHC
LAST: $135.90 (+3.35%) • MKT CAP: $12.97B
forward-pe
21.3x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 29.00% | -15.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 33.3x | -17.50 | EHC | /valuation <GO> |
| Free Cash Flow Yield | 2.92% | 3.47% | -0.55 | ABBV | /fcf-yield <GO> |
| Operating Margin | 11.60% | 24.60% | -13.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 9.50% | 6.90% | +2.60 | EHC | /net-margins <GO> |
| Revenue Growth (YoY) | 10.50% | 8.60% | +1.90 | EHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 2.27% | -1.72 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.47 | 5.33 | -1.86 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | EHC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.2 | 72.8 | -3.55 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.90 | 1.15 | -0.25 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.3x | 113.1x | -91.80 | EHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.97B | $513.86B | -$500.89B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EHC REV | ABBV REV | EHC GROSS % | ABBV GROSS % | EHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.94B | $61.16B | 44.0% | 70.2% | $367.1M | $17.82B |
| FY 2024 | $5.37B | $56.33B | 44.0% | 70.0% | $268.6M | $17.83B |
| FY 2023 | $4.80B | $54.32B | 44.0% | 44.0% | $178.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EHC // BETA 0.90
ABBV // BETA 1.15